New pill shows promise for rare lymphoma – no chemo needed yet
NCT ID NCT07441993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called orelabrutinib in 30 people with a slow-growing blood cancer called marginal zone lymphoma who have not had any prior treatment. The goal is to see if the drug can shrink or control the cancer. Participants take the drug by mouth and are monitored for side effects and how well the cancer responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Nantong University
RECRUITINGNantong, Jiangsu, China
-
Beijing Tongren Hospital, Capital Medical University
RECRUITINGBeijing, China
-
Hematology Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Jiangsu Province People's Hospital
RECRUITINGNanjing, Jiangsu, China
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, China
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, China
-
Shandong Cancer Hospital & Institute
RECRUITINGJinan, Shandong, China
-
Shandong Provincial Hospital
RECRUITINGJinan, Shandong, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
-
The Second Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, China
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
Xiangyang Central Hospital
RECRUITINGXiangyang, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Smartwatches track hidden heart risk in blood cancer patients
- New drug combo aims to tackle Hard-to-Treat lymphoma